Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 4.25% w/ Dextrose 25% provides amino acids for protein synthesis and dextrose as a caloric source, supporting nitrogen balance and energy requirements in parenteral nutrition.
Provides essential amino acids and dextrose for parenteral nutrition; amino acids serve as substrates for protein synthesis, while dextrose supplies caloric energy.
Adults: 1-3 L/day intravenously through central line. Infusion rate initially 50-100 mL/hour, titrate to achieve protein and calorie requirements.
Individualized based on protein and calorie requirements; typical adult dose: 500-2000 mL/day intravenously, infused at a rate not exceeding 200 mL/hour.
None Documented
None Documented
Amino acids: 10-30 min (rapid distribution). Dextrose: glucose half-life ~1.5-2 h in euglycemia; prolonged in renal impairment. Clinically, continuous infusion maintains steady state without significant accumulation.
Variable, dependent on individual amino acids and metabolic state; clinical context reflects continuous infusion without distinct terminal phase.
Amino acids are metabolized; nitrogen waste is excreted renally as urea. Dextrose is metabolized to CO2 and water. Renal excretion accounts for >95% of nitrogen elimination. Minimal biliary/fecal elimination.
Renal, primarily as urea and free amino acids; minimal biliary/fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution